Investigation of risk factors for in-hospital death in complex high-risk and indicated patients undergoing percutaneous coronary intervention assisted by extracorporeal membrane oxygenation

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026 Apr;38(4):325-330. doi: 10.3760/cma.j.cn121430-20250804-00421.ABSTRACTOBJECTIVE: To analyze the baseline data and clinical characteristics of patients with complex high-risk and indicated patients (CHIP) undergoing percutaneous coronary intervention (PCI)

C Conglong Hu

Walras modulates sex-dependent endoplasmic reticulum stress in cardiomyopathy

Front Physiol. 2026 May 11;17:1740128. doi: 10.3389/fphys.2026.1740128. eCollection 2026.ABSTRACTINTRODUCTION: Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Most heart cardiomyopathies result in an increased need for protein

F Francisco J Martinez-Amaro

Role of cardiac mast cells in cardiovascular diseases: a review

PeerJ. 2026 May 22;14:e21320. doi: 10.7717/peerj.21320. eCollection 2026.ABSTRACTMast cells are multifunctional immune cells that play complex roles in maintaining tissue homeostasis and disease pathogenesis. They are also involved in inflammation, lymphangiogenesis, and tissue remodeling by releasi

L Li-Min Wang

Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial

Drug Des Devel Ther. 2026 May 20;20:587488. doi: 10.2147/DDDT.S587488. eCollection 2026.ABSTRACTPURPOSE: This 8-week, randomized, double-blind study evaluated the efficacy and safety of low-dose combination of telmisartan 20 mg/S-amlodipine 2.5 mg (T20/SA2.5) versus telmisartan 40 mg (T40) monothera

J Jong-Chan Youn